目的 探讨骨康胶囊联合阿法骨化醇片治疗老年骨质疏松的临床疗效。方法 选取2015年9月-2016年9月京东中美医院收治的老年骨质疏松患者117例为研究对象，按随机数字表法将患者分为对照组（58例）和治疗组（59例）。对照组口服阿法骨化醇片，1片/次，1次/d。治疗组在对照组基础上口服骨康胶囊，4粒/次，3次/d。两组患者均连续治疗6个月。观察两组的临床疗效，比较两组的骨密度、骨代谢和生活质量。结果 治疗后，对照组和治疗组的总有效率分别为82.76%、96.61%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组腰椎L₂~L₄和髋部骨密度均显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组骨密度明显高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清骨钙素（BGP）、血清碱性磷酸酶（BALP）、酒石酸酸性磷酸酶5b（TRACP-5b）水平均显著下降，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组这些骨代谢生化指标明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组健康状况调查问卷（SF-36）评分均显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组SF-36评分明显高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 骨康胶囊联合阿法骨化醇片治疗老年骨质疏松具有较好的临床疗效，可调节骨代谢，提高骨密度，改善患者的生活质量，具有一定临床推广应用价值。

Objective To discuss the clinical efficacy of Gukang Capsules combined with Alfacalcidol Tablets in treatment of senile osteoporosis. Methods Patients (117 cases) with senile osteoporosis in Jingdong Zhongmei Hospital from September 2015 to September 2016 were randomly divided into the control group (58 cases) and the treatment group (59 cases). Patients in the control group were po administered with Alfacalcidol Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Gukang Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and bone mineral density, bone metabolism, and quality of life in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.76% and 96.61%, respectively, and there was difference between two groups (P < 0.05). After treatment, lumbar vertebra L₂-L₄ and hip bone mineral density in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of BGP, BALP, and TRACP-5b in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the SF-36 scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the SF-36 score in the treatment group was significantly higher than that in the control group, with significant difference between two groups (P < 0.05). Conclusion GuKang Capsules combined with Alfacalcidol Tablets has clinical curative effect in treatment of senile osteoporosis, can regulate the bone metabolism, increase the bone mineral density, and improve the quality of life, which has a certain clinical application value.